Spots Global Cancer Trial Database for metastatic esophageal adenocarcinoma

Every month we try and update this database with for metastatic esophageal adenocarcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial	NCT06203600	Advanced Esopha... Advanced Gastri... Advanced Gastro... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Metastatic Esop... Metastatic Gast... Metastatic Gast... Unresectable Es... Unresectable Ga... Unresectable Ga...	Biospecimen Col... Computed Tomogr... Magnetic Resona... Nivolumab Paclitaxel Questionnaire A... Ramucirumab	18 Years -	National Cancer Institute (NCI)
Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca	NCT04921904	Metastatic Esop... Metastatic Gast...	Abemaciclib Ramucirumab	18 Years -	Baylor Research Institute
A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer	NCT06251973	Metastatic Esop... Advanced Unrese... Metastatic Gast... Metastatic Gast... Metastatic Esop... Metastatic Esop... Metastatic Gast... Metastatic Gast... Unresectable Es... Unresectable Es... Unresectable Ga... Unresectable Ga... Unresectable Ga...	AgenT-797 Botensilimab Balstilimab Ramucirumab Paclitaxel	18 Years -	Memorial Sloan Kettering Cancer Center
Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body	NCT04248452	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Metastatic Esop... Metastatic Gast... Oligometastatic... Oligometastatic... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag...	Capecitabine Fluorouracil Leucovorin Leucovorin Calc... Oxaliplatin Radiation Thera...	18 Years -	Eastern Cooperative Oncology Group
Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca	NCT04921904	Metastatic Esop... Metastatic Gast...	Abemaciclib Ramucirumab	18 Years -	Baylor Research Institute
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer	NCT01142388	Metastatic Esop... Metastatic Esop... Metastatic Gast... Recurrent Esoph... Recurrent Esoph... Recurrent Esoph... Recurrent Gastr... Stage IV Esopha...	Cixutumumab Laboratory Biom... Paclitaxel Pharmacological...	18 Years -	National Cancer Institute (NCI)
Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca	NCT04921904	Metastatic Esop... Metastatic Gast...	Abemaciclib Ramucirumab	18 Years -	Baylor Research Institute
Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma	NCT05651594	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Metastatic Esop... Metastatic Gast... Unresectable Es... Unresectable Ga...	Biopsy Biospecimen Col... Computed Tomogr... Fluorouracil Leucovorin Oxaliplatin Pembrolizumab Propranolol Hyd... Questionnaire A...	18 Years -	Roswell Park Cancer Institute
Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers	NCT04460937	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Distal Esophagu... Gastric Cardia ... Metastatic Esop... Metastatic Esop... Metastatic Gast... Metastatic Mali... Metastatic Mali... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Unresectable Es... Unresectable Es... Unresectable Es... Unresectable Ga...	Adavosertib Radiation Thera...	18 Years -	National Cancer Institute (NCI)
Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca	NCT04921904	Metastatic Esop... Metastatic Gast...	Abemaciclib Ramucirumab	18 Years -	Baylor Research Institute

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: